Related Experiment Video
Updated: Jul 11, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
Bioreductive activation and drug chaperoning in cobalt pharmaceuticals
Matthew D Hall1, Timothy W Failes, Natsuho Yamamoto
1Centre for Heavy Metals Research, School of Chemistry, The University of Sydney, NSW 2006, Australia.
Abstract:
The potential for cobalt(III) complexes in medicine, as chaperones of bioactive ligands, and to target tumours through bioreductive activation, has been examined over the past 20 years. Despite this, chemical properties such as reduction potential and carrier ligands required for optimal tumour targeting and drug delivery have not been optimised. Here we review the chemistry of cobalt(III) drug design, and recent developments in the understanding of the cellular fate of these drugs.
More Related Videos
09:27Immobilization of Multi-biocatalysts in Alginate Beads for Cofactor Regeneration and Improved Reusability
Published on: April 22, 2016
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Related Concept Videos
Drug Biotransformation: Overview
Drug Biotransformation: Overview
Drug Discovery: Overview
Prodrugs
Prodrugs help overcome...
Drug Metabolism: Phase II Reactions
Drug-Receptor Bonds
In...